Evidence map›Paper›PMID 30614474›Full record

GuidelineThe Lancet. Oncology2019

Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium.

Eva Clemens, Marry M van den Heuvel-Eibrink, Renée L Mulder, Leontien C M Kremer, Melissa M Hudson, Roderick Skinner, Louis S Constine, Johnnie K Bass, Claudia E Kuehni, Thorsten Langer and 22 more

2 registry-linked trialsAbstract readPractice GuidelineReview
PubMed Full text at PMC Publisher
In one paragraph

Guideline in The Lancet. Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 58 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03297034 recruitingnot on this map

Swiss Childhood Cancer Survivor Study (SCCSS)

Typeobservational_patient_registrySponsorUniversity of BernRan2007 to 2050Enrolled4,136ConditionsChildhood Cancer
NCT06036407 nacompletednot on this mapstarted 2022, after this paper: background citation

Improving Access to Screening for Hearing Loss After Childhood Cancer - a Novel Community-based Approach

TypeinterventionalSponsorUniversity of BernRan2022 to 2024Enrolled476ConditionsChildhood Cancer, Hearing LossArmsHearing test
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. The relevance of ototoxicity induced by radiotherapy.Radiation oncology (London, England) · 2023
    Pooled it
  4. Guideline
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Assay platform non-comparability as a foundational constraint on the synthesis of prestin evidence in cochlear biomarker research.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  10. Prestin as a potential biomarker for cochlear injury: Current evidence and future directions.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Eva ClemensPrincess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Hematology and Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands.
Marry M van den Heuvel-EibrinkPrincess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Renée L MulderPrincess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Leontien C M KremerPrincess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Melissa M HudsonDepartment of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.
Roderick SkinnerDepartment of Pediatric and Adolescent Hematology/Oncology and Children's Hematopoietic Stem Cell Transplant Unit, Great North Children's Hospital and Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
Louis S ConstineDepartments of Radiation Oncology and Pediatrics, University of Rochester Medical Center, Rochester, New York, NY, USA.
Johnnie K BassRehabilitation Services, St Jude Children's Research Hospital, Memphis, TN, USA.
Claudia E KuehniSwiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Department of Pediatrics, Children's University Hospital of Bern, University of Bern, Bern, Switzerland.
Thorsten LangerPediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck, Germany.
Elvira C van DalenPrincess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Edith BardiDepartment of Pediatrics and Adolescent Medicine, Kepler Universitätsklinikum, Linz, Austria.
Nicolas-Xavier BonneUniversity of Lille, CHU Lille, Otology and Otoneurology, Lille, France.
Penelope R BrockGreat Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Beth BrooksRehabilitation Services, St Jude Children's Research Hospital, Memphis, TN, USA; Audiology and Speech Pathology Department, British Columbia's Children's Hospital, Vancouver, BC, Canada; School of Audiology and Speech Sciences, University of British Columbia, Vancouver, BC, Canada.
Bruce CarletonPharmaceutical Outcomes Programme, British Columbia's Children's Hospital, Vancouver, BC, Canada; Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Eric CaronDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.
Kay W ChangDepartment of Otolaryngology, Stanford University, Palo Alto, CA, USA.
Karen JohnstonKids Cancer Centre, Sydney Children's Hospital, High Street, Randwick, NSW, Australia.
Kristin KnightDepartment of Pediatric Audiology, Child Development and Rehabilitation Center, Doernbecher Children's Hospital, Oregon Health and Science University, Portland, OR, USA.
Paul C NathanDepartment of Pediatrics, Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Etan OrgelChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA, USA; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Pinki K PrasadDepartment of Pediatrics, Louisiana State University Health Sciences Center, New Orleans, LA, USA; Division of Pediatric Hematology/Oncology, Children's Hospital of New Orleans, New Orleans, LA, USA.
Jan RottenbergDepartment of Otolaryngology and Head and Neck Surgery, St Ann's University Hospital Brno, Masaryk University, Brno, Czech Republic.
Katrin ScheinemannDivision of Pediatric Hematology/Oncology, Hospital for Children and Adolescents, Cantonal Hospital Aarau, Aarau, Switzerland; Division of Pediatric Hematology/Oncology, University for Children's Hospital Basel, Basel, Switzerland; Division of Pediatric Hematology/Oncology, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada.
Andrica C H de VriesPrincess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Hematology and Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands.
Thomas WalwynDepartment of Pediatric and Adolescent Oncology, Perth Children's Hospital, Nedlands, WA, Australia; School of Medicine, University of Western Australia, Perth, WA, Australia.
Annette WeissSwiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany.
Antoinette Am Zehnhoff-DinnesenDepartment of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University of Münster, Münster, Germany.
Richard J CohnKids Cancer Centre, Sydney Children's Hospital, High Street, Randwick, NSW, Australia; School of Women's and Children's Health, University of New South Wales Medicine, Sydney, NSW, Australia.
Wendy LandierInstitute for Cancer Outcomes and Survivorship, Department of Pediatrics, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, AL, USA. Electronic address: wlandier@peds.uab.edu.
International Guideline Harmonization Group ototoxicity group

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
Cancer Research UK 8156NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA014236NCI NIH HHS P30 CA021765NCI NIH HHS U10 CA180886
6 · The paper itself

Abstract

Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems-such as speech and language, social-emotional development, and learning difficulties-for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.

Indexed as

Cancer SurvivorsAdolescentAntineoplastic AgentsChildCranial IrradiationDelivery of Health CareEvidence-Based MedicineHumansNeoplasmsOtotoxicityPlatinum CompoundsPopulation SurveillanceYoung AdultAntineoplastic AgentsPlatinum Compounds

Identifiers

PMID30614474
PMCPMC7549756

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.